Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PULM NASDAQ:UMRX NASDAQ:VTGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePULMPulmatrix$1.40$1.31$1.16▼$9.15$5.11M1.9525,129 shs23,652 shsUMRXCogent Biosciences$36.95+3.7%$10.50$0.29▼$3.72$1.57B3.931.22 million shs2.23 million shsVTGNVistaGen Therapeutics$0.58$0.60$0.43▼$5.14$22.83M0.31573,106 shs677,771 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePULMPulmatrix0.00%+5.26%+12.00%-34.58%-82.07%UMRXCogent Biosciences0.00%0.00%0.00%+8.68%+421.89%VTGNVistaGen Therapeutics0.00%+5.94%-7.79%-8.57%-73.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePULMPulmatrix$1.40$1.31$1.16▼$9.15$5.11M1.9525,129 shs23,652 shsUMRXCogent Biosciences$36.95+3.7%$10.50$0.29▼$3.72$1.57B3.931.22 million shs2.23 million shsVTGNVistaGen Therapeutics$0.58$0.60$0.43▼$5.14$22.83M0.31573,106 shs677,771 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePULMPulmatrix0.00%+5.26%+12.00%-34.58%-82.07%UMRXCogent Biosciences0.00%0.00%0.00%+8.68%+421.89%VTGNVistaGen Therapeutics0.00%+5.94%-7.79%-8.57%-73.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePULMPulmatrix 1.00SellN/AN/AUMRXCogent Biosciences 0.00N/AN/AN/AVTGNVistaGen Therapeutics 1.80Reduce$0.9564.87% UpsideCurrent Analyst Ratings BreakdownLatest VTGN, PULM, and UMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026VTGNVistaGen Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026PULMPulmatrix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPULMPulmatrix$7.81M0.65N/AN/A$2.45 per share0.57UMRXCogent Biosciences$22.50M69.74N/AN/A$1.04 per share35.53VTGNVistaGen Therapeutics$490K46.59N/AN/A$2.44 per share0.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePULMPulmatrix-$5.16M-$1.23N/AN/AN/AN/A-107.84%-91.58%8/12/2026 (Estimated)UMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/AVTGNVistaGen Therapeutics-$51.42M-$1.89N/AN/AN/AN/A-109.72%-89.62%6/16/2026 (Estimated)Latest VTGN, PULM, and UMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/1/2026Q4 2026VTGNVistaGen Therapeutics-$0.3377N/AN/AN/A$0.40 millionN/A6/16/2026Q4 2026VTGNVistaGen Therapeutics-$0.3367N/AN/AN/A$0.40 millionN/A5/15/2026Q1 2026PULMPulmatrixN/A-$0.32N/A-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthPULMPulmatrixN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/AVTGNVistaGen TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPULMPulmatrixN/A4.964.96UMRXCogent Biosciences0.182.902.90VTGNVistaGen TherapeuticsN/A4.674.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPULMPulmatrix11.84%UMRXCogent Biosciences26.39%VTGNVistaGen Therapeutics78.39%Insider OwnershipCompanyInsider OwnershipPULMPulmatrix0.62%UMRXCogent Biosciences31.50%VTGNVistaGen Therapeutics2.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePULMPulmatrix203.65 million3.63 millionNot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableVTGNVistaGen Therapeutics4039.62 million38.49 millionOptionableVTGN, PULM, and UMRX HeadlinesRecent News About These CompaniesVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety DisorderJune 9, 2026 | businesswire.comVistaGen Therapeutics (VTGN) to Release Earnings on TuesdayJune 9, 2026 | americanbankingnews.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmJune 1, 2026 | prnewswire.comVistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical OfficerMay 19, 2026 | businesswire.comIs Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?May 19, 2026 | insidermonkey.comVistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderMay 12, 2026 | businesswire.comVistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety DisorderMay 8, 2026 | businesswire.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmApril 29, 2026 | globenewswire.comVistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock DropApril 28, 2026 | prnewswire.comVistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseApril 22, 2026 | businesswire.comKuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law FirmApril 20, 2026 | newsfilecorp.comNVistaGen Faces Nasdaq Audit Committee Compliance SetbackApril 2, 2026 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTGNMarch 17, 2026 | globenewswire.comBronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmMarch 16, 2026 | globenewswire.comCLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline TonightMarch 16, 2026 | businesswire.comVTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud LawsuitMarch 16, 2026 | prnewswire.comVTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmMarch 16, 2026 | prnewswire.comVistagen Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - VTGNMarch 16, 2026 | prnewswire.comVTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - VTGNMarch 15, 2026 | newsfilecorp.comNVTGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026March 15, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTGN, PULM, and UMRX Company DescriptionsPulmatrix NASDAQ:PULM$1.40 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.Cogent Biosciences NASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.VistaGen Therapeutics NASDAQ:VTGN$0.58 0.00 (0.00%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$0.59 +0.02 (+3.09%) As of 06/12/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Viasat's Orbiting Profits: Space Force Jackpot? What to Expect From Q2 Earnings as Tech Strength Broadens ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
